Pharming's Q4 2024 revenue increased by 14% year-over-year to $92.7 million, with RUCONEST® revenue rising 9% and Joenja® revenue surging 66%. Operating profit grew significantly, reflecting strong product performance and increased patient enrollments. The company continued investments in research and acquisitions to expand its rare disease portfolio.